{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:26:43Z","timestamp":1791638803519,"version":"4.3.4"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"am","delay-in-days":321,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.yebeh.2023.109227","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T10:57:48Z","timestamp":1684321068000},"page":"109227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Investigation of the efficacy and adverse effects of lacosamide over 36\u00a0months"],"prefix":"10.1016","volume":"144","author":[{"given":"Kei","family":"Wakabayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Osaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Yamagishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Kuwajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Muramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Yamagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2023.109227_b0005","doi-asserted-by":"crossref","first-page":"R14","DOI":"10.1186\/ar2121","article-title":"Antinociceptive efficacy of lacosamide in the monosodium iodoacetate rat model for osteoarthritis pain","volume":"9","author":"Beyreuther","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.yebeh.2023.109227_b0010","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1527-3458.2007.00001.x","article-title":"Lacosamide: a review of preclinical properties","volume":"13","author":"Beyreuther","year":"2007","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.yebeh.2023.109227_b0015","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/epi.13466","article-title":"Lacosamide use in children with epilepsy: Retention rate and effect of concomitant sodium channel blockers in a large cohort","volume":"57","author":"McGinnis","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2023.109227_b0020","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eplepsyres.2014.11.021","article-title":"Current understanding of the mechanism of action of the antiepileptic drug lacosamide","volume":"110","author":"Rogawski","year":"2015","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2023.109227_b0025","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/jnr.23136","article-title":"Comparative study of lacosamide and classical sodium channel blocking antiepileptic drugs on sodium channel slow inactivation","volume":"91","author":"Niespodziany","year":"2013","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.yebeh.2023.109227_b0030","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/epi.14071","article-title":"Long-term efficacy of add-on lacosamide treatment in children and adolescents with refractory epilepsies: A single-center observational study","volume":"59","author":"Rosati","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2023.109227_b0035","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/epi.13671","article-title":"Instruction manual for the ILAE 2017 operational classification of seizure types","volume":"58","author":"Fisher","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2023.109227_b0040","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/epi.13670","article-title":"Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Fisher","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2023.109227_b0045","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2023.109227_b0050","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.yebeh.2017.11.024","article-title":"The effectiveness and safety of lacosamide in children with epilepsy in a clinical practice setting","volume":"79","author":"Sanmart\u00ed-Vilaplana","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2023.109227_b0055","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.seizure.2012.12.009","article-title":"Lacosamide in pediatric and adult patients: comparison of efficacy and safety","volume":"22","author":"Verrotti","year":"2013","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2023.109227_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.107814","article-title":"Safety, efficacy, and tolerability of lacosamide for the treatment of epilepsy in pediatric patients in Uygur, China","volume":"117","author":"Zhao","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2023.109227_b0065","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1111\/epi.13869","article-title":"Lacosamide in the treatment of patients with epilepsy and intellectual disabilities: A long-term study of 136 patients","volume":"58","author":"B\u00f6ttcher","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2023.109227_b0070","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.yebeh.2016.10.029","article-title":"Long-term lacosamide retention-Real-world experience at a tertiary epilepsy center in Ireland","volume":"68","author":"McGinty","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2023.109227_b0075","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.2165\/11594640-000000000-00000","article-title":"Novel medications for epilepsy","volume":"71","author":"Fattore","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.yebeh.2023.109227_b0080","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.seizure.2020.04.016","article-title":"Efficacy and tolerability of treatment with lacosamide in children: Postmarketing experience from the Middle East","volume":"79","author":"Hmaimess","year":"2020","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2023.109227_b0085","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/11587550-000000000-00000","article-title":"A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs","volume":"24","author":"Sake","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2023.109227_b0090","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.yebeh.2011.11.026","article-title":"Rational polytherapy with lacosamide in clinical practice: results of a Spanish cohort analysis RELACOVA","volume":"23","author":"Villanueva","year":"2012","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2023.109227_b0095","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.braindev.2013.07.003","article-title":"Lacosamide as an adjunctive therapy in pediatric patients with refractory focal epilepsy","volume":"36","author":"Kim","year":"2014","journal-title":"Brain Develop"},{"key":"10.1016\/j.yebeh.2023.109227_b0100","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejpn.2013.08.006","article-title":"Efficacy and safety of lacosamide in infants and young children with refractory focal epilepsy","volume":"18","author":"Grosso","year":"2014","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.yebeh.2023.109227_b0105","doi-asserted-by":"crossref","unstructured":"Brenner J, Majoie HJM, van Beek S, Carpay JA. The retention of lacosamide in patients with epilepsy and intellectual disability in three specialised institutions. Seizure 2017;52:123\u2013130. Letter to the Editors.","DOI":"10.1016\/j.seizure.2017.09.017"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505023001464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505023001464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:52:12Z","timestamp":1761504732000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505023001464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":21,"alternative-id":["S1525505023001464"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2023.109227","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigation of the efficacy and adverse effects of lacosamide over 36\u00a0months","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2023.109227","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109227"}}